Why Smaller M&A Deals Boost Biopharma Growth

As biopharma companies navigate a rapidly changing landscape filled with challenges to patent cliffs and the Inflation Reduction Act, many have turned to high-profile acquisitions in search of growth. However, insights from McKinsey’s report on M&A trends and industry leaders, such as Anshul Mangal, suggest that this high-priced strategy may not be the best path to long-term success.

In the article published by Fierce Pharma, “For biopharma M&A, the best returns come from small deals: analysts”, Anshul Mangal, President, Project Farma – a Precision for Medicine company, emphasizes the advantages of smaller, strategic acquisitions. He argues that:

• Smaller deals spread risk more effectively than larger acquisitions.
• They can drive innovation in emerging fields like cell and gene therapy.
• Retaining key personnel is crucial for successful integration and long-term success.

Additionally, Anshul stresses the importance of acquiring companies with strong clinical programs, which are essential for navigating today’s competitive environment.

Read the full article “For biopharma M&A, the best returns come from small deals: analysts”, published in Fierce Pharma for a deeper understanding of how a smaller-scale M&A approach can lead to sustainable growth and competitive advantage.